Risk factors for chronic graft-versus-host disease after bone marrow transplantation: A retrospective single centre analysis

Bone Marrow Transplantation

Volumn 22, Issue 8, 1998, Pages 755-761

  Carlens, S ^a   Ringden O ^a   Remberger, M ^a   Lonnqvist B ^a   Hagglund H ^a   Klaesson, S ^a   Mattsson, J ^a   Svahn, B M ^a   Winiarski, J ^a   Ljungman, P ^a   Aschan, J ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Bone marrow transplantation; Graft versus host disease; Risk factors

Indexed keywords

CYCLOSPORIN A; METHOTREXATE;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; BONE MARROW TRANSPLANTATION; CHILD; FEMALE; GENDER; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; MALE; MULTIVARIATE ANALYSIS; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK FACTOR; SCHOOL CHILD; SIBLING;

EID: 0031737114     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701423     Document Type: Article

References (46)

1. Rouquette-Gally AM, Boyeldieu D, Gluckman E et al. Autoimmunity in 28 patients after allogeneic bone marrow transplantation: comparison with Sjögren syndrome and scleroderma. Br J Haematol 1987; 66: 45-47.
2. Lister J, Messner H, Keystone AE et al. Autoantibody analysis of patients with graft-versus-host disease. J Clin Lab Immunol 1987; 24: 19-23.
3. Sullivan KM, Shulman HM, Storb R et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood 1981; 57: 267-276,
4. Atkinson K, Storb R, Prentice RL et al. Analysis of late infections in 89 long-term survivors of bone marrow transplantation. Blood 1979; 53: 720-731.
5. Shulman HM, Sale GE, Lerner KG et al. Chronic cutaneous graft-versus-host disease in man. Am J Pathol 1978; 91: 545-570.
6. Ringdén O, Paulin T, Lönnqvist B, Nilsson B. An analysis of factors predisposing to chronic graft-versus-host disease, Exp Hematol 1985; 13:1062-1067.
7. Atkinson K, Horowitz MM, van Bekkum DW et al. Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood 1990; 75: 2459-2464.
8. Storb R, Prentice RL, Sullivan KM et al. Predictive factors in chronic graft-versus-host disease in patients with aplastic anemia treated by marrow transplantation from HLA-identical siblings. Ann Intern Med 1983; 98: 461-466.
9. Weiden PL, Sullivan KM, Fluornoy N et al. Antileukemic effect of chronic graft-versus-host disease. Contribution to improved survival after allogeneic marrow transplantation. New Engl J Med 1981; 304: 1529-1533.
10. Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555-562.
11. Sullivan KM, Weiden PL, Storb R et al. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood 1989; 73: 1720-1728.
12. Ringdén O, Labopin M, Gluckman E et al. Graft-versus-leuke- mia effect in afiogeneic marrow transplant recipients with acute leukemia is maintained using cyclosporin A combined with methotrexate as prophylaxis. Bone Marrow Transplant 1996; 18: 921-929.
13. Boström L, Ringdén O, Jacobsen N et al. A European multicenter study of chronic graft-versus-host disease. The role of cytomegalovirus serology in recipients and donors - acute graft-versus-host disease and splenectomy. Transplantation 1990; 49: 1100-1105.
14. Lönnqvist B, Ringdén O, Wahren B et al. Cytomegalovirus infections associated with and preceding chronic graft-versus-host disease. Transplantation 1984; 38: 465-468.
15. Jacobsen N, Andersen JK, Skinhöj P et al. Correlation between donor cytomegalovirus immunity and chronic graft-versus-host disease after allogeneic bone marrow transplantation. Scand J Haematol 1986; 36: 499-506.
16. Ringdén O, Horowitz MM, Sondel P et al. Methotrexate, cyclosporine or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukaemia in older adults. Blood 1993; 81: 1094-1101.
17. Ringdén O, Klaesson S, Sundberg B et al. Decreased incidence of graft-versus-host disease and improved survival with methotrexate combined with cyclosporin, as compared to monotherapy in recipients of bone marrow from donors other than HLA-identical siblings. Bone Marrow Transplant 1992; 9: 19-25.
18. Ringdén O, Båryd I, Johansson B et al. Increased mortality by septicemia, interstitial pneumonitis and pulmonary fibrosis among bone marrow transplant recipients receiving an increased mean dose rate of total irradiation, Acta Radiol Oncol 1983; 22: 423-428.
19. Ringdén O, Ruutu T, Remberger M et al. A randomized trial comparing busulphan vs total body irradiation in allogeneic marrow transplant recipients with leukemia. Blood 1984; 83: 2723-2730.
20. Ringdén O, Pihlstedt P, Markling L et al. Prevention of graft-versus-host disease with T-cell depletion or cyclosporin and methotrexate. A randomized trial in adult leukaemia marrow recipients. Bone Marrow Transplant 1991; 7: 221-226.
21. Ringdén O, Groth CG, Aschan J et al. Bone marrow transplantation for metabolic disorders at Huddinge Hospital. Transplant P roc 1990; 22: 198-202.
22. Thomas ED, Storb R, Clift RA et al. Bone-marrow transplantation. Parts I and II. New Engl J Med 1975; 292: 832-843, 895-902.
23. Shulman HM, Sullivan KM, Weiden PL et al. Chronic graft-versus-host syndrome in man, A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204-217.
24. Storb R, Epstein RB, Graham TC, Thomas ED. Methotrexate regimens for control of graft-versus-host disease in dogs with allogeneic marrow grafts. Transplantation 1970; 9: 240-246.
25. Ringdén O, Bäckman L, Lönnqvist B et al. A randomized trial comparing the use of cyclosporin and methotrexate for graft-versus-host disease prophylaxis in bone marrow transplant recipients with haematologic malignancies. Bone Marrow Transplant 1986; 1: 41-51.
26. Prentice HG, Blacklock HAA, Janossy G et al. Depletion of T lymphocytes in donor marrow prevents significant graft-versus-host disease in matched allogeneic leukaemic marrow transplant recipients. Lancet 1984; 1: 472-475.
27. Deeg HJ, Storb R, Appelbaum FR et al. Combined immunosuppression with cyclosporine and methotrexate in dogs given bone marrow grafts from DLA-haploidentical littermates. Transplantation 1984; 37: 62-65.
28. Storb R, Deeg HJ, Whitehead J et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft-versus-host disease after marrow transplantation for leukemia. New Engl J Med 1986; 314: 729-735.
29. Aschan J, Ringdén O, Andström E et al. Individualized prophylaxis against graft-versus-host disease in leukemic marrow transplant recipients. Bone Marrow Transplant 1994; 14: 79-87.
30. Sullivan KM, Witherspoon RP, Storb R et al. Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-vs-host disease. Blood 1988; 72: 555-561.
31. Sullivan KM, Witherspoon RP, Storb R et al. Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic-graft-vs-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. Blood 1988; 72: 546-554.
32. Hymes SR, Morison WL, Farmer ER et al. Methoxalen and ultraviolet A radiation in treatment of chronic cutaneous graft-versus-host reaction. J Am Acad Dermatol 1985; 12: 30-37.
33. Deeg HJ, Ullrich SE. Ultraviolet irradiation for the prevention and treatment of allosensitization and graft-versus-host disease. In: Atkinson K (ed). Clinical Bone Marrow Transplantation: A Reference Textbook. Cambridge University Press: Cambridge, 1994, pp 668-675.
34. Vogelsang GB, Santos GW, Colvin OM, Chen T. Thalidomide for graft-versus-host disease. Lancet 1988; 1: 827.
35. Socié G, Devergie A, Cosset JM et al. Low-dose (one gray) total-lymphoid irradiation for extensive, drug-resistant chronic graft-versus-host disease. Transplantation 1990; 49: 1191-1200.
36. Besnier DP, Chabannes D, Mahe B et al. Treatment of graft-versus-host disease by extracorporeal photochemotherapy: a pilot study. Transplantation 1997; 64: 49-54.
37. Ljungman P, Griffiths P. Definitions of cytomegalovims infections and disease. In: Plotkin SA, Michelson S (eds). Multidisciplinary Approach to Understanding Cytomegalovims Disease. Excerpta Medica International Congress Series: Amsterdam, 1993; 1032: 233-240.
38. Peto R, Pike MC, Armitage P et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977; 35: 1-39.
39. Cox DR. Regression models and life-tables. J R Stat Soc 1972; 34: 187-220.
40. Aschan J, Ringdén O, Sundberg B et al. Methotrexate combined with cyclosporine A decreases graft-versus-host disease, but increases leukemic relapse compared to monotherapy. Bone Marrow Transplant 1991; 7: 113-119.
41. Gale RP, Bortin MM, van Bekkum DW et al. Risk factors for acute graft-versus-host disease. Br J Haematol 1987; 67: 397-106.
42. Kolb HJ, Mittermüller J, Clemm CH et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukaemia in marrow transplant patients. Blood 1990; 76: 2462-2465.
43. Balkwill FR. Interferons. Lancet 1989; I: 1060-1063.
44. Hägglund H, Boström L, Remberger M et al. Risk factors for acute graft-versus-host disease in 291 consecutive HLA-identical bone marrow transplant recipients. Bone Marrow Transplant 1995; 16: 747-753.
45. Carlens S, Ringdén O, Aschan J et al. Risk-factors in bone marrow transplant recipients with leukemia. Increased relapse risk in patients treated with ciprofloxacin for gut-decontamination. Clin Transplant 1998; 12: 84-92.
46. Ringdén O, Remberger M, Carlens S et al. Transplantation with unrelated bone marrow in leukaemic patients above 40 years of age. Bone Marrow Transplant 1998; 21: 43-49.